Background Excessive angiogenesis has emerged as an essential feature of tumor development and appears to be regulated in part by extracellular matrix proteins. Scientists at National Jewish Health have identified an extracellular matrix protein (designated MAGP-2) that acts as a pro-angiogenic agent in vivo.
A target for inhibiting angiogenesis in cancer and other angiogenesis-dependent diseases
Stimulating neovascularization by administration of MAGP-2 to ischemic tissues in coronary artery disease, stroke, and delayed wound healing
A diagnostic biomarker, especially for cancer
Advantages of Invention Because of its extracellular nature, MAGP-2 can be easily detectable and targetable by antibody-based technologies for example.
State of Development Our scientists have shown the following:
MAGP-2 is over expressed in human uterine tumor samples and has been associated with ovarian and head & neck cancer
Endothelial cell expression of MAGP-2 increases during angiogenesis in vitro
MAGP-2 stimulates angiogenic sprouting in 3-dimensional collagen cultures
MAGP-2 increases endothelial cell proliferation and invasion in vitro
Significant enhancement of neovascularization when MAGP-2 was implanted into mice through matrigel plugs
MAGP-2 increases tumor size and angiogenesis in mice
Licensing Status This technology is available for licensing.
For Further Information, Contact: Emmanuel Hilaire, PhD Director Technology Transfer Office National Jewish Health 1400 Jackson Street, Room M206b Denver, CO 80206 Voice: 303.398.1262 Fax: 303.270.2352 HilaireE@njhealth.org